Latest News and Press Releases
Want to stay updated on the latest news?
-
H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining...
-
Talicia® is approved by the U.S. FDA and promoted by RedHill’s U.S. sales force--Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week®...
-
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care...
-
Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the...
-
RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint, with top-line results...
-
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA® are expected before year’s end The ERADICATE Hp2 study enrolled 455 patients with...
-
400 of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2)RedHill expects to complete enrollment...